[en] Duchenne muscular dystrophy (DMD) is an X-linked condition caused by a deficiency of functional dystrophin protein. Patients experience progressive muscle weakness, cardiomyopathy and have a decreased life expectancy. Standards of care, including treatment with steroids, and multidisciplinary approaches have extended the life expectancy and improved the quality of life of patients. In the last 30 years, several compounds have been assessed in preclinical and clinical studies for their ability to restore functional dystrophin levels or to modify pathways involved in DMD pathophysiology. However, there is still an unmet need with regards to a disease-modifying treatment for DMD and the attrition rate between early-phase and late-phase clinical development remains high. Currently, there are 40 compounds in clinical development for DMD, including gene therapy and antisense oligonucleotides for exon skipping. Only five of them have received conditional approval in one jurisdiction subject to further proof of efficacy. In this review, we present data of another 16 compounds that failed to complete clinical development, despite positive results in early phases of development in some cases. We examine the reasons for the high attrition rate and we suggest solutions to avoid similar mistakes in the future.
Disciplines :
Pediatrics Neurology
Author, co-author :
Markati, Theodora; University of Oxford, MDUK Oxford Neuromuscular Center > Department of Paediatrics
De Waele, Liesbeth; KU Leuven > Department of Development and Regeneration & Department of Paediatric Neurology
Schara-Schmidt, Urlike; University of Duisburg-Essen > 4Department of Pediatric Neurology, Center for Neuromuscular Diseases
Servais, Laurent ; Université de Liège - ULiège > Département des sciences cliniques > Département des sciences cliniques
Language :
English
Title :
Lessons Learned from Discontinued Clinical Developments in Duchenne Muscular Dystrophy.
Aartsma-Rus A. Arechavala-Gomeza V. (2018). Why Dystrophin Quantification Is Key in the Eteplirsen Saga. Nat. Rev. Neurol. 14 (8), 454–456. 10.1038/s41582-018-0033-8
Aartsma-Rus A. Corey D. R. (2020). The 10th Oligonucleotide Therapy Approved: Golodirsen for Duchenne Muscular Dystrophy. Nucleic Acid Ther. 30 (2), 67–70. 10.1089/nat.2020.0845
Aartsma-Rus A. Krieg A. M. (2017). FDA Approves Eteplirsen for Duchenne Muscular Dystrophy: The Next Chapter in the Eteplirsen Saga. Nucleic Acid Ther. 27 (1), 1–3. 10.1089/nat.2016.0657
Aartsma-Rus A. Morgan J. Lonkar P. Neubert H. Owens J. Binks M. et al. (2019). Report of a TREAT-NMD/World Duchenne Organisation Meeting on Dystrophin Quantification Methodology. J. Neuromuscul. Dis. 6 (1), 147–159. 10.3233/JND-180357
Alter J. Lou F. Rabinowitz A. Yin H. Rosenfeld J. Wilton S. D. et al. (2006). Systemic Delivery of Morpholino Oligonucleotide Restores Dystrophin Expression Bodywide and Improves Dystrophic Pathology. Nat. Med. 12 (2), 175–177. 10.1038/nm1345
Barp A. Bello L. Politano L. Melacini P. Calore C. Polo A. et al. (2015). “Genetic Modifiers of Duchenne Muscular Dystrophy and Dilated Cardiomyopathy, Editor A. Kumar, PLoS One 10, e0141240. 10.1371/journal.pone.0141240
Barthélémy I. Calmels N. Weiss R. B. Tiret L. Vulin A. Wein N. et al. (2020). X-linked Muscular Dystrophy in a Labrador Retriever Strain: Phenotypic and Molecular Characterisation. Skelet Muscle 10 (1), 23. 10.1186/s13395-020-00239-0
Bello L. D'Angelo G. Villa M. Fusto A. Vianello S. Merlo B. et al. (2020). Genetic Modifiers of Respiratory Function in Duchenne Muscular Dystrophy. Ann. Clin. Transl Neurol. 7 (5), 786–798. 10.1002/acn3.51046
Bello L. Morgenroth L. P. Gordish-Dressman H. Hoffman E. P. McDonald C. M. Cirak S. et al. (2016). DMD Genotypes and Loss of Ambulation in the CINRG Duchenne Natural History Study. Neurology 87 (4), 401–409. 10.1212/WNL.0000000000002891
Birnkrant D. J. Bushby K. Bann C. M. Alman B. A. Apkon S. D. Blackwell A. et al. (2018a). Diagnosis and Management of Duchenne Muscular Dystrophy, Part 2: Respiratory, Cardiac, Bone Health, and Orthopaedic Management. Lancet Neurol. 17 (4), 347–361. 10.1016/S1474-4422(18)30025-5
Birnkrant D. J. Bushby K. Bann C. M. Apkon S. D. Blackwell A. Brumbaugh D. et al. (2018b). Diagnosis and Management of Duchenne Muscular Dystrophy, Part 1: Diagnosis, and Neuromuscular, Rehabilitation, Endocrine, and Gastrointestinal and Nutritional Management. Lancet Neurol. 17 (3), 251–267. 10.1016/S1474-4422(18)30024-3
Birnkrant D. J. Bushby K. Bann C. M. Apkon S. D. Blackwell A. Colvin M. K. et al. (2018c). Diagnosis and Management of Duchenne Muscular Dystrophy, Part 3: Primary Care, Emergency Management, Psychosocial Care, and Transitions of Care across the Lifespan. Lancet Neurol. 17 (5), 445–455. 10.1016/S1474-4422(18)30026-7
Buyse G. M. Goemans N. van den Hauwe M. Meier T. (2013). Effects of Glucocorticoids and Idebenone on Respiratory Function in Patients with Duchenne Muscular Dystrophy. Pediatr. Pulmonol 48 (9), 912–920. 10.1002/ppul.22688
Buyse G. M. Van der Mieren G. Erb M. D'hooge J. Herijgers P. Verbeken E. et al. (2009). Long-term Blinded Placebo-Controlled Study of SNT-MC17/idebenone in the Dystrophin Deficient Mdx Mouse: Cardiac protection and Improved Exercise Performance. Eur. Heart J. 30 (1), 116–124. 10.1093/eurheartj/ehn406
Buyse G. M. Voit T. Schara U. Straathof C. S. D'Angelo M. G. Bernert G. et al. (2017). Treatment Effect of Idebenone on Inspiratory Function in Patients with Duchenne Muscular Dystrophy. Pediatr. Pulmonol 52 (4), 508–515. 10.1002/ppul.23547
Buyse G. M. Voit T. Schara U. Straathof C. S. M. D'Angelo M. G. Bernert G. et al. (2015). Efficacy of Idebenone on Respiratory Function in Patients with Duchenne Muscular Dystrophy Not Using Glucocorticoids (DELOS): a Double-Blind Randomised Placebo-Controlled Phase 3 Trial. Lancet 385 (9979), 1748–1757. 10.1016/S0140-6736(15)60025-3
Campbell C. McMillan H. J. Mah J. K. Tarnopolsky M. Selby K. McClure T. et al. (2017). Myostatin Inhibitor ACE-031 Treatment of Ambulatory Boys with Duchenne Muscular Dystrophy: Results of a Randomized, Placebo-Controlled Clinical Trial. Muscle Nerve 55 (4), 458–464. 10.1002/mus.25268
Ciafaloni E. Kumar A. Liu K. Pandya S. Westfield C. Fox D. J. et al. (2016). “Age at Onset of First Signs or Symptoms Predicts Age at Loss of Ambulation in Duchenne and Becker Muscular Dystrophy: Data from the MD STARnet,” in Age at Onset of First Signs or Symptoms Predicts Age at Loss of Ambulation in Duchenne and Becker Muscular Dystrophy: Data from the MD STARnet. Editor Matthews D. J. (Amsterdam, Netherlands: J. Pediatr. Rehabil. Med, IOS Press) 9, 5–11. 10.3233/prm-160361
de Feraudy Y. Ben Yaou R. Wahbi K. Stalens C. Stantzou A. Laugel V. et al. (2021). Very Low Residual Dystrophin Quantity Is Associated with Milder Dystrophinopathy. Ann. Neurol. 89 (2), 280–292. 10.1002/ana.25951
de la Peña N. Luna E. Castellanos A. (2017). Influencia de los esteroides en los parametros de la marcha en distrofia de Duchenne. Rehabilitación 51 (1), 5–10. 10.1016/j.rh.2016.09.006
Dhillon S. (2020). Viltolarsen: First Approval. Drugs 80 (10), 1027–1031. 10.1007/s40265-020-01339-3
Doorenweerd N. (2020). Combining Genetics, Neuropsychology and Neuroimaging to Improve Understanding of Brain Involvement in Duchenne Muscular Dystrophy - a Narrative Review. Neuromuscul. Disord. 30 (6), 437–442. 10.1016/j.nmd.2020.05.001
Dovari A. Inuganti B. Nadimpally J. Vatturi S. M. Hyderboini R. Goyal R. (2021). PRO38 Twenty Years of Clinical Trials in Duchenne Muscular Dystrophy: A Low Clinical Drug Development Success. Value in Health 24, S204. 10.1016/j.jval.2021.04.1023
Duan D. Goemans N. Takeda S. Mercuri E. Aartsma-Rus A. (2021). Duchenne Muscular Dystrophy. Nat. Rev. Dis. Primers 7 (1), 13. 10.1038/s41572-021-00248-3
Egorova T. V. Galkin I. I. Ivanova Y. V. Polikarpova A. V. (2021). “Duchenne Muscular Dystrophy Animal Models,” in Animal Models in Medicine and Biology (London, United Kingdom: IntechOpen). (Online ahead of printing). 10.5772/intechopen.96738
Finanger E. Vandenborne K. Finkel R. S. Lee Sweeney H. Tennekoon G. Yum S. et al. (2019). Phase 1 Study of Edasalonexent (CAT-1004), an Oral NF-Κb Inhibitor, in Pediatric Patients with Duchenne Muscular Dystrophy. J. Neuromuscul. Dis. 6 (1), 43–54. 10.3233/JND-180341
Finkel R. S. Finanger E. Vandenborne K. Sweeney H. L. Tennekoon G. Shieh P. B. et al. (2021). Disease-modifying Effects of Edasalonexent, an NF-Κb Inhibitor, in Young Boys with Duchenne Muscular Dystrophy: Results of the MoveDMD Phase 2 and Open Label Extension Trial. Neuromuscul. Disord. 31 (5), 385–396. 10.1016/j.nmd.2021.02.001
Finkel R. S. McDonald C. M. Lee Sweeney H. Finanger E. Neil Knierbein E. Wagner K. R. et al. (2021). A Randomized, Double-Blind, Placebo-Controlled, Global Phase 3 Study of Edasalonexent in Pediatric Patients with Duchenne Muscular Dystrophy: Results of the PolarisDMD Trial. J. Neuromuscul. Dis. 8 (5), 769–784. 10.3233/JND-210689
Fouarge E. Monseur A. Boulanger B. Annoussamy M. Seferian A. M. De Lucia S. et al. (2021). Hierarchical Bayesian Modelling of Disease Progression to Inform Clinical Trial Design in Centronuclear Myopathy. Orphanet J. Rare Dis. 16 (1), 3. 10.1186/s13023-020-01663-7
Goemans N. Klingels K. van den Hauwe M. Boons S. Verstraete L. Peeters C. et al. (2013). Six-minute Walk Test: Reference Values and Prediction Equation in Healthy Boys Aged 5 to 12 Years. PLoS One 8 (12), e84120. 10.1371/journal.pone.0084120
Goemans N. Mercuri E. Belousova E. Komaki H. Dubrovsky A. McDonald C. M. et al. (2018). A Randomized Placebo-Controlled Phase 3 Trial of an Antisense Oligonucleotide, Drisapersen, in Duchenne Muscular Dystrophy. Neuromuscul. Disord. 28 (1), 4–15. 10.1016/j.nmd.2017.10.004
Goemans N. Signorovitch J. Sajeev G. Yao Z. Gordish-Dressman H. McDonald C. M. et al. (2020). Suitability of External Controls for Drug Evaluation in Duchenne Muscular Dystrophy. Neurology 95 (10), e1381–91. 10.1212/WNL.0000000000010170
Goemans N. Wong B. Van den Hauwe M. Signorovitch J. Sajeev G. Cox D. et al. (2020). Prognostic Factors for Changes in the Timed 4-stair Climb in Patients with Duchenne Muscular Dystrophy, and Implications for Measuring Drug Efficacy: A Multi-Institutional Collaboration. PLoS One 15 (6), e0232870. 10.1371/journal.pone.0232870
Goemans N. M. Tulinius M. van den Hauwe M. Kroksmark A. K. Buyse G. Wilson R. J. et al. (2016). Long-Term Efficacy, Safety, and Pharmacokinetics of Drisapersen in Duchenne Muscular Dystrophy: Results from an Open-Label Extension Study. PLoS One 11 (9), e0161955. 10.1371/journal.pone.0161955
Haberkamp M. Moseley J. Athanasiou D. de Andres-Trelles F. Elferink A. Rosa M. M. et al. (2019). European Regulator's Views on a Wearable-Derived Performance Measurement of Ambulation for Duchenne Muscular Dystrophy Regulatory Trials. Neuromuscul. Disord. 29 (7), 514–516. 10.1016/j.nmd.2019.06.003
Hightower R. M. Alexander M. S. (2018). Genetic Modifiers of Duchenne and Facioscapulohumeral Muscular Dystrophies. Muscle Nerve 57 (1), 6–15. 10.1002/mus.25953
Hogrel J. Y. Decostre V. Ledoux I. de Antonio M. Niks E. H. de Groot I. et al. (2020). Normalized Grip Strength Is a Sensitive Outcome Measure through All Stages of Duchenne Muscular Dystrophy. J. Neurol. 267 (7), 2022–2028. 10.1007/s00415-020-09800-9
Hogrel J. Y. Wary C. Moraux A. Azzabou N. Decostre V. Ollivier G. et al. (2016). Longitudinal Functional and NMR Assessment of Upper Limbs in Duchenne Muscular Dystrophy. Neurology 86 (11), 1022–1030. 10.1212/WNL.0000000000002464
Koch C. Buono S. Menuet A. Robé A. Djeddi S. Kretz C. et al. (2020). Myostatin: a Circulating Biomarker Correlating with Disease in Myotubular Myopathy Mice and Patients. Mol. Ther. Methods Clin. Dev. 17, 1178–1189. 10.1016/j.omtm.2020.04.022
Larcher T. Lafoux A. Tesson L. Remy S. Thepenier V. François V. et al. (2014). Characterization of Dystrophin Deficient Rats: a New Model for Duchenne Muscular Dystrophy. PLoS One 9 (10), e110371. 10.1371/journal.pone.0110371
Le Guiner C. Servais L. Montus M. Larcher T. Fraysse B. Moullec S. et al. (2017). Long-term Microdystrophin Gene Therapy Is Effective in a Canine Model of Duchenne Muscular Dystrophy. Nat. Commun. 8 (1), 16105. 10.1038/ncomms16105
Leung D. G. Herzka D. A. Thompson W. R. He B. Bibat G. Tennekoon G. et al. (2014). Sildenafil Does Not Improve Cardiomyopathy in Duchenne/Becker Muscular Dystrophy. Ann. Neurol. 76 (4), 541–549. 10.1002/ana.24214
Lilien C. Gasnier E. Gidaro T. Seferian A. Grelet M. Vissière D. et al. (2019). Home-based Monitor for Gait and Activity Analysis. J. Vis. Exp. (150), 59668. 10.3791/59668
Lu Q. L. Rabinowitz A. Chen Y. C. Yokota T. Yin H. Alter J. et al. (2005). Systemic Delivery of Antisense Oligoribonucleotide Restores Dystrophin Expression in Body-wide Skeletal Muscles. Proc. Natl. Acad. Sci. U S A. 102 (1), 198–203. 10.1073/pnas.0406700102
Mariot V. Joubert R. Hourdé C. Féasson L. Hanna M. Muntoni F. et al. (2017). Downregulation of Myostatin Pathway in Neuromuscular Diseases May Explain Challenges of Anti-myostatin Therapeutic Approaches. Nat. Commun. 8 (1), 1859. 10.1038/s41467-017-01486-4
Mayer O. H. Leinonen M. Rummey C. Meier T. Buyse G. M. Group D. S. (2017). Efficacy of Idebenone to Preserve Respiratory Function above Clinically Meaningful Thresholds for Forced Vital Capacity (FVC) in Patients with Duchenne Muscular Dystrophy. J. Neuromuscul. Dis. 4 (3), 189–198. 10.3233/JND-170245
Mazzone E. S. Coratti G. Sormani M. P. Messina S. Pane M. D'Amico A. et al. (2016). Timed Rise from Floor as a Predictor of Disease Progression in Duchenne Muscular Dystrophy: An Observational Study. PLoS One 11 (3), e0151445. 10.1371/journal.pone.0151445
Mazzone E. S. Messina S. Vasco G. Main M. Eagle M. D'Amico A. et al. (2009). Reliability of the North Star Ambulatory Assessment in a Multicentric Setting. Neuromuscul. Disord. 19 (7), 458–461. 10.1016/j.nmd.2009.06.368
McClorey G. Moulton H. M. Iversen P. L. Fletcher S. Wilton S. D. (2006). Antisense Oligonucleotide-Induced Exon Skipping Restores Dystrophin Expression In Vitro in a Canine Model of DMD. Gene Ther. 13 (19), 1373–1381. 10.1038/sj.gt.3302800
McCroskery S. Thomas M. Platt L. Hennebry A. Nishimura T. McLeay L. et al. (2005). Improved Muscle Healing through Enhanced Regeneration and Reduced Fibrosis in Myostatin-Null Mice. J. Cel Sci 118 (Pt 15), 3531–3541. 10.1242/jcs.02482
McDonald C. M. Henricson E. K. Abresch R. T. Duong T. Joyce N. C. Hu F. et al. (2018a). Long-term Effects of Glucocorticoids on Function, Quality of Life, and Survival in Patients with Duchenne Muscular Dystrophy: a Prospective Cohort Study. Lancet 391 (10119), 451–461. 10.1016/S0140-6736(17)32160-8
Mcdonald C. M. Henricson E. K. Abresch R. T. Florence J. M. Eagle M. Gappmaier E. et al. (2013). The 6-minute Walk Test and Other Endpoints in Duchenne Muscular Dystrophy: Longitudinal Natural History Observations over 48 Weeks from a Multicenter Study. Muscle Nerve 48 (3), 343–356. 10.1002/mus.23902
McDonald C. M. Wong B. Flanigan K. M. Wilson R. de Kimpe S. Lourbakos A. et al. (2018b). Placebo-controlled Phase 2 Trial of Drisapersen for Duchenne Muscular Dystrophy. Ann. Clin. Transl Neurol. 5 (8), 913–926. 10.1002/acn3.579
Mercuri E. Muntoni F. Osorio A. N. Tulinius M. Buccella F. Morgenroth L. P. et al. (2020). Safety and Effectiveness of Ataluren: Comparison of Results from the STRIDE Registry and CINRG DMD Natural History Study. J. Comp. Eff. Res. 9 (5), 341–360. 10.2217/cer-2019-0171
Mercuri E. Signorovitch J. E. Swallow E. Song J. Ward S. J. Group D. M. D. I. et al. (2016). Categorizing Natural History Trajectories of Ambulatory Function Measured by the 6-minute Walk Distance in Patients with Duchenne Muscular Dystrophy. Neuromuscul. Disord. 26 (9), 576–583. 10.1016/j.nmd.2016.05.016
Muntoni F. Domingos J. Manzur A. Y. Mayhew A. Guglieri M. Network U. K. N. et al. (2019b). Categorising Trajectories and Individual Item Changes of the North Star Ambulatory Assessment in Patients with Duchenne Muscular Dystrophy. PLoS One 14 (9), e0221097. 10.1371/journal.pone.0221097
Muntoni F. Tejura B. Spinty S. Roper H. Hughes I. Layton G. et al. (2019a). A Phase 1b Trial to Assess the Pharmacokinetics of Ezutromid in Pediatric Duchenne Muscular Dystrophy Patients on a Balanced Diet. Clin. Pharmacol. Drug Dev. 8 (7), 922–933. 10.1002/cpdd.642
Muntoni F. Maresh K. Davies K. Harriman S. Layton G. Rosskamp R. et al. (2017). PhaseOut DMD: a Phase 2, Proof of Concept, Clinical Study of Utrophin Modulation with Ezutromid. Neuromuscul. Disord. 27, S217. 10.1016/j.nmd.2017.06.443
Nakamura K. Fujii W. Tsuboi M. Tanihata J. Teramoto N. Takeuchi S. et al. (2015). Generation of Muscular Dystrophy Model Rats with a CRISPR/Cas System. Sci. Rep. 4 (1), 5635. 10.1038/srep05635
Nio Y. Tanaka M. Hirozane Y. Muraki Y. Okawara M. Hazama M. et al. (2017). Phosphodiesterase 4 Inhibitor and Phosphodiesterase 5 Inhibitor Combination Therapy Has Antifibrotic and Anti-inflammatory Effects in Mdx Mice with Duchenne Muscular Dystrophy. FASEB J. 31 (12), 5307–5320. 10.1096/fj.201700249R
Osorio A. N. Tulinius M. Buccella F. Desguerre I. Kirschner J. Mercuri E. et al. (2020). Pulmonary Function in Non-ambulatory Patients with Nonesense Mutation Duchenne Muscular Dystrophy: Stride Registry and Cinrg Dnhs Matched Cohort Analysis. Muscle and Nerve 62 (Suppl. 1), S6–S7. 10.1007/s00259-020-04988-4
Peay H. L. Biesecker B. B. Wilfond B. S. Jarecki J. Umstead K. L. Escolar D. M. et al. (2018). Barriers and Facilitators to Clinical Trial Participation Among Parents of Children with Pediatric Neuromuscular Disorders. Clin. Trials 15 (2), 139–148. 10.1177/1740774517751118
Percival J. M. Whitehead N. P. Adams M. E. Adamo C. M. Beavo J. A. Froehner S. C. (2012). Sildenafil Reduces Respiratory Muscle Weakness and Fibrosis in the Mdx Mouse Model of Duchenne Muscular Dystrophy. J. Pathol. 228 (1), 77–87. 10.1002/path.4054
Poleur M. Ulinici A. Daron A. Schneider O. Farra F. D. Demonceau M. et al. (2021). Normative Data on Spontaneous Stride Velocity, Stride Length, and Walking Activity in a Non-controlled Environment. Orphanet J. Rare Dis. 16 (1), 318. 10.1186/s13023-021-01956-5
Pradhan S. Das A. (2018). Change in the Natural Profile of Duchenne Muscular Dystrophy with the Judicious Use of Steroids. Neurol. India 66 (3), 893–895. 10.4103/0028-3886.232304
Ricotti V. Ridout D. A. Pane M. Main M. Mayhew A. Mercuri E. et al. (2016). The NorthStar Ambulatory Assessment in Duchenne Muscular Dystrophy: Considerations for the Design of Clinical Trials. J. Neurol. Neurosurg. Psychiatry 87 (2), 149–155. 10.1136/jnnp-2014-309405
Rooney W. D. Berlow Y. A. Triplett W. T. Forbes S. C. Willcocks R. J. Wang D. J. et al. (2014). Modeling Disease Trajectory in Duchenne Muscular Dystrophy. Neurology 94 (15), e1622–33. 10.1212/WNL.0000000000009244
Ropars J. Gravot F. Ben Salem D. Rousseau F. Brochard S. Pons C. (2020). Muscle MRI: A Biomarker of Disease Severity in Duchenne Muscular Dystrophy? A Systematic Review. Neurology 94 (3), 117–133. 10.1212/WNL.0000000000008811
Ryan N. J. (2014). Ataluren: First Global Approval. Drugs 74 (14), 1709–1714. 10.1007/s40265-014-0287-4
Rybalka E. Timpani C. A. Debruin D. A. Bagaric R. M. Campelj D. G. Hayes A. (2020). The Failed Clinical Story of Myostatin Inhibitors against Duchenne Muscular Dystrophy: Exploring the Biology behind the Battle. Cells 9 (12), 10. 10.3390/cells9122657
Schreiber A. Brochard S. Rippert P. Fontainecarbonel S. Peudenier S. Payan C. et al. (2016). The Natural History of Duchenne Muscular Dystrophy with Corticosteroids Using the Motor Function Measure. Develop. Med. Child Neurol. 58 (Suppl. 6), 25. 10.1111/dmcn.12341
Seferian A. M. Moraux A. Annoussamy M. Canal A. Decostre V. Diebate O. et al. (2015). Upper Limb Strength and Function Changes during a One-Year Follow-Up in Non-ambulant Patients with Duchenne Muscular Dystrophy: an Observational Multicenter Trial. PLoS One 10 (2), e0113999. 10.1371/journal.pone.0113999
Servais L. Mercuri E. Straub V. Guglieri M. Seferian A. M. Scoto M. et al. Long-term Safety and Efficacy Data of Golodirsen in Ambulatory Patients with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A First-In-Human, Multicenter, Two-Part, Open-Label, Phase 1/2 Trial.
Servais L. Straathof C. S. M. Schara U. Klein A. Leinonen M. Hasham S. et al. (2019). Long-term Data with Idebenone on Respiratory Function Outcomes in Patients with Duchenne Muscular Dystrophy. Neuromuscul. Disord. 30 (1), 5–16. 10.1016/j.nmd.2019.10.008
Shirley M. (2021). Casimersen: First Approval. Drugs 81 (7), 875–879. 10.1007/s40265-021-01512-2
Soblechero‐Martín P. López‐Martínez A. Puente‐Ovejero L. Vallejo‐Illarramendi A. Arechavala‐Gomeza V. (2021). Utrophin Modulator Drugs as Potential Therapies for Duchenne and Becker Muscular Dystrophies. Neuropathol. Appl. Neurobiol 47 (6), 711–723. 10.1111/nan.12735
Starosta A. Konieczny P. (2021). Therapeutic Aspects of Cell Signaling and Communication in Duchenne Muscular Dystrophy. Cell Mol Life Sci 78 (11), 4867–4891. 10.1007/s00018-021-03821-x
Sun C. Shen L. Zhang Z. Xie X. (2020). Therapeutic Strategies for Duchenne Muscular Dystrophy: An Update. Genes (Basel) 11 (8), 837. 10.3390/genes11080837
Tejura B. Spinty S. Roper H. Hughes I. Majumdar A. Harriman S. et al. (2017). Overcoming Pharmacokinetic Challenges to Drug Administration in Duchenne Muscular Dystrophy: Lessons from Phase 1 Development of Ezutromid. Eur. J. Paediatric Neurol. 21 (Suppl. 1), e93. 10.1016/j.ejpn.2017.04.1207
Timpani C. A. Hayes A. Rybalka E. (2017). Therapeutic Strategies to Address Neuronal Nitric Oxide Synthase Deficiency and the Loss of Nitric Oxide Bioavailability in Duchenne Muscular Dystrophy. Orphanet J. Rare Dis. 12 (1), 100. 10.1186/s13023-017-0652-y
Timpani C. A. Mamchaoui K. Butler-Browne G. Rybalka E. (2020). Nitric Oxide (NO) and Duchenne Muscular Dystrophy: NO Way to Go? Antioxidants 9 (12), 1268. 10.3390/antiox9121268
Tinsley J. Deconinck N. Fisher R. Kahn D. Phelps S. Gillis J. M. et al. (1998). Expression of Full-Length Utrophin Prevents Muscular Dystrophy in Mdx Mice. Nat. Med. 4 (12), 1441–1444. 10.1038/4033
van Deutekom J. C. Bremmer-Bout M. Janson A. A. Ginjaar I. B. Baas F. den Dunnen J. T. et al. (2001). Antisense-induced Exon Skipping Restores Dystrophin Expression in DMD Patient Derived Muscle Cells. Hum. Mol. Genet. 10 (15), 1547–1554. 10.1093/hmg/10.15.1547
Victor R. G. Sweeney H. L. Finkel R. McDonald C. M. Byrne B. Eagle M. et al. (2017). A Phase 3 Randomized Placebo-Controlled Trial of Tadalafil for Duchenne Muscular Dystrophy. Neurology 89 (17), 1811–1820. 10.1212/WNL.0000000000004570
Voit T. Topaloglu H. Straub V. Muntoni F. Deconinck N. Campion G. et al. (2014). Safety and Efficacy of Drisapersen for the Treatment of Duchenne Muscular Dystrophy (DEMAND II): an Exploratory, Randomised, Placebo-Controlled Phase 2 Study. Lancet Neurol. 13 (10), 987–996. 10.1016/S1474-4422(14)70195-4
Wagner K. R. Abdel-Hamid H. Z. Mah J. K. Campbell C. Guglieri M. Muntoni F. et al. (2020). Randomized Phase 2 Trial and Open-Label Extension of Domagrozumab in Duchenne Muscular Dystrophy. Neuromuscul. Disord. 30 (6), 492–502. 10.1016/j.nmd.2020.05.002
Wagner K. R. Liu X. Chang X. Allen R. E. (2005). Muscle Regeneration in the Prolonged Absence of Myostatin. Proc. Natl. Acad. Sci. U S A. 102 (7), 2519–2524. 10.1073/pnas.0408729102
Wagner K. R. McPherron A. C. Winik N. Lee S. J. (2002). Loss of Myostatin Attenuates Severity of Muscular Dystrophy in Mdx Mice. Ann. Neurol. 52 (6), 832–836. 10.1002/ana.10385
Wagner K. R. (2020). The Elusive Promise of Myostatin Inhibition for Muscular Dystrophy. Curr. Opin. Neurol. 33 (5), 621–628. 10.1097/WCO.0000000000000853
Wagner K. R. Wong B. L. Byrne B. J. Tian C. Jacobsen L. K. Tirucherai G. S. et al. (2019). A Phase 1b/2 Study of the Anti-myostatin Adnectin RG6206 (BMS-986089) in Ambulatory Boys with Duchenne Muscular Dystrophy: A 72-week Treatment Update. Neurol. Conf. 71st Annu. Meet. Am. Acad. Neurol. AAN. 92 (15 Suppl. 1), P1.6–062.
Wells D. J. (2019). What Is the Level of Dystrophin Expression Required for Effective Therapy of Duchenne Muscular Dystrophy? J. Muscle Res. Cel Motil 40 (2), 141–150. 10.1007/s10974-019-09535-9
Wilkinson I. V. L. Perkins K. J. Dugdale H. Moir L. Vuorinen A. Chatzopoulou M. et al. (2019). Chemical Proteomics and Phenotypic Profiling Identifies the Aryl Hydrocarbon Receptor as a Molecular Target of the Utrophin Modulator Ezutromid. Angew. Chem. Int. Ed. Engl. 59 (6), 2420–2428. 10.1002/anie.201912392
